Progenics Pharmaceuticals Inc. of Tarrytown, N.Y., has beenawarded $50,000 under Phase I of a Small Business InnovationResearch Program Grant by the National Institute of Allergyand Infectious Diseases.

The grant will allow Progenics to expand its AIDS vaccineprogram by developing a system to produce large quantities ofgp120, a protein present on the outer surface or "envelope" ofthe human immunodeficiency virus.

(c) 1997 American Health Consultants. All rights reserved.